Navigation Links
PharmaEngine, Inc. and Merrimack Pharmaceuticals, Inc. Enter into a Licensing and Collaboration Agreement on PEP02 (MM-398), Nanoliposomal Irinotecan
Date:5/9/2011

TAIPEI, May 9, 2011 /PRNewswire-Asia/ -- PharmaEngine, Inc. and Merrimack Pharmaceuticals, Inc. announced today the execution of an agreement under which PharmaEngine grants back to Merrimack the rights to develop, manufacture, and commercialize PEP02 (known under the designation of MM-398 by Merrimack) in Asia and Europe, with the exception of Taiwan.  

Under the agreement, PharmaEngine will receive an upfront payment of US$10 million, and is eligible to receive up to an additional US$210 million of milestone payments, as well as tiered royalties on net sales in Asia and Europe.  Merrimack is responsible for all product development costs in the licensed territories, while PharmaEngine retains the exclusive development and commercialization rights in Taiwan, and plays a role in clinical and regulatory activities pursuant to an integrated global development plan.

"We are thrilled to collaborate with Merrimack to advance the development of PEP02 (MM-398).  Drug development is like a relay race; PharmaEngine has developed this drug candidate from preclinical to phase II stages, and we believe that Merrimack is well-positioned to take the baton and accelerate development of this product through global commercialization," said C. Grace Yeh, Ph.D., President and Chief Executive Officer of PharmaEngine. "Today's announcement signifies the commitment of both companies to develop an innovative nanoparticle therapy that addresses significant unmet medical needs for cancer patients who are refractory to available treatments."

About PEP02 (MM-398)

PEP02 is a novel and highly stable nanoliposomal formulation of irinotecan.  PharmaEngine has tested PEP02 in several human clinical studies to date, including four phase I studies and two phase II studies in gastric and pancreatic cancers.  Both phase II studies met their primary endpoints of response rate and 3-month survival.  Data from both studies were recently p
'/>"/>

SOURCE PharmaEngine, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks
2. Biostar Pharmaceuticals, Inc. Receives New Advertising Approval from Shaanxi SFDA for Marketing Xin Aoxing Capsule
3. Massachusetts General Hospital Center Reignites Methods in Bioengineering Conference
4. RIKEN and Max Planck Society establish Joint Research Center for Systems Chemical Biology
5. What motivates environmental activists, policymakers? asks new research center
6. Massachusetts General Hospital Center Reignites Methods in Bioengineering Conference
7. Green industry knowledge center introduced
8. Intelligent design: Engineered protein fragment blocks the AIDS virus from entering cells
9. Altitude Research Center wins major Pentagon grants
10. Boston Medical Center receives support from CVS Caremark Charitable Trust
11. National Biophotonic Sensors and Systems Center announced
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/14/2014)... of researchers, led by the Chinese Academy of Agricultural ... Genetics a brief genomic history of tomato breeding, ... plant. , The C.M. Rick Tomato Genetics Resource Center ... study by providing seed of both cultivated tomato varieties ... on the first tomato genome sequence completed just two ...
(Date:10/14/2014)... Over the past decades, we have seen numerous tragic ... needs of infants for social contact and stimulation has ... , Infancy and childhood are critical life ... generation of research suggests that enriched environments, full of ... function. In contrast, deprivation and stress may compromise cortical ...
(Date:10/14/2014)... oral biologic medication has successfully treated chronic, precancerous inflammation ... study authored by an MD/PhD student in the University ... , The study is featured on the cover of ... was published online ahead of print in September. The ... Inflammatory cells in the colon, or polyps, are very ...
Breaking Biology News(10 mins):Institutional rearing may increase risk attention-deficit disorder 2Oral drug reduces formation of precancerous polyps in the colon, UB researchers find 2Oral drug reduces formation of precancerous polyps in the colon, UB researchers find 3
... When a foreign object such as a catheter enters the ... into a slick coating a biofilm that is ... cannot be defeated by a basic approach of conventional means. ... reveals the key players in the network and how they ...
... 2010 China PharmaHub Corp. (OTC Bulletin Board: ... agreement to be a distributor for Integrated Biometrics ("IB"), ...  PharmaHub will have the exclusive distribution rights in China, ... to sell IB products to customers in the Pharmaceutical, ...
... soldiers in the battlefield healthy, the U.S. Army is exploring ... Current techniques for analyzing water in the field can take ... Lipkens of Western New England College in Springfield, Massachusetts and ... They are working on an alternative technology that uses sound ...
Cached Biology News:Research provides new leads in the case against drug-resistant biofilms 2China PharmaHub Signs Distribution Agreement with Integrated Biometrics 2China PharmaHub Signs Distribution Agreement with Integrated Biometrics 3
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
(Date:10/20/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... to $5.8 million and provides a good start to Q4.  The ... America and one in the Middle East ... record levels," said Peter Bruijns , President & CEO. "Total ... Q3 than they have been for any complete year since the ...
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ...
(Date:10/20/2014)... 20, 2014 Local veterinary surgeon, Dr. ... investigational study of donor stem cells for dogs with ... therapy and has performed clinical stem cell therapy for ... to determine if a single injection of donor stem ... help reduce pain and inflammation in the treated joints. ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... Approve Merger With Integra on October 11, ... ... September 5 IsoTis, Inc.,(NASDAQ: ISOT ) ("IsoTis"), an orthobiologics ... U.S. Securities and,Exchange Commission ("SEC") in connection with the IsoTis-Integra,LifeSciences Holdings ...
... WEST BRIDGEWATER, Mass., Sept. 5 Pressure,BioSciences, Inc. ... has received,approval to CE Mark the Barocycler NEP2320, ... (PCT) instrument. The,Company also announced that it has ... indicating that the Barocycler NEP2320 has been found ...
... 5 Thermo Fisher,Scientific Inc. (NYSE: TMO ... the instrument sales business of Davis Inotek Instruments, ... and excludes its,related calibration services. Davis Instruments is ... instruments, serving customers in a,wide range of industries ...
Cached Biology Technology:IsoTis Files Definitive Proxy Statement 2IsoTis Files Definitive Proxy Statement 3IsoTis Files Definitive Proxy Statement 4Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 2Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 3Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 4Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 2Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 3Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 4
Recombinant Equine IL-6...
dithiothreitol (DTT) Reactive Dyes and Chemicals Thiol-Reactive Dyes, Haptens and Quenchers Reducing Agents...
GRADIENT MAKER, 30 ML, 1 EA. Category: Protein Vertical Instruments....
Recombinant Rat Leptin, CF...
Biology Products: